The GNG12 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HeLa cell line, designed for studying GNG12-dependent signaling pathways. This product features targeted disruption of the GNG12 gene, which encodes the gamma-12 subunit of heterotrimeric G proteins, providing a loss-of-function model for investigating G?¦?-mediated signal transduction.
The parental HeLa cell line is a human cervical adenocarcinoma epithelial cell line that is HPV18-positive and characterized by p53 degradation via HPV E6, leading to immortalization. Widely used in cancer research, virology, and cell signaling studies, HeLa cells provide a robust platform for gene knockout experiments, offering consistent growth and well-characterized signaling networks.
GNG12 forms a stable complex with GNB1 to constitute the G?¦? dimer, which dissociates from G?? subunits upon GPCR activation. This dimer transmits signals to downstream effectors, including PI3K, PLC-??, and ion channels. Specifically, G?¦? directly activates PI3K, leading to AKT phosphorylation and mTOR pathway engagement, and stimulates PLC-?? to generate DAG and IP3, triggering calcium mobilization and PKC activation. GNG12 also participates in MAPK signaling via ERK1/2 and regulates RhoA-mediated cytoskeletal dynamics. Upstream, GNG12 is engaged by chemokine receptors such as CXCR4 and CCR5, as well as various GPCRs including dopamine and adrenergic receptors. Interacting proteins like RGS proteins and phosducin modulate G?¦? activity, while GPR54 and PDZ-domain proteins such as PICK1 facilitate context-dependent signaling.
In HeLa cells, which endogenously express multiple GPCRs and chemokine receptors, GNG12 knockout allows precise dissection of G?¦?-dependent processes. Given the role of GNG12 in cell migration and proliferation??critical in cervical cancer progression??this model enables the study of chemotactic responses and invasive behavior. The disruption of GNG12 may alter PI3K/AKT and RhoA pathways, affecting cytoskeletal rearrangement and survival signals. Researchers can thus evaluate how G?¦? signaling contributes to oncogenic phenotypes in an HPV-driven cancer background.
Typical applications include functional characterization of G?¦? effectors using Western blotting for phospho-AKT and phospho-ERK, RT-qPCR for knockout validation, and Transwell migration assays to assess chemotaxis. Calcium flux assays with Fluo-4, cAMP measurements, and PIP3 ELISA quantify second messenger changes. RhoA activation assays and co-immunoprecipitation of G?¦? complexes further elucidate signaling mechanisms. This polyclonal knockout population is suitable for drug target validation and high-throughput screening for G?¦? inhibitors. For more information, please contact Ascent Research.
